- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- SEP-225289, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 31
- States / cities
- Encino, California • Garden Grove, California • Irvine, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
- Interventions
- dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • Atlanta, Georgia + 2 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo Comparator
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • National City, California • Paramount, California + 37 more
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 65
- States / cities
- Beverly Hills, California • Encino, California • Escondido, California + 52 more
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- dasotraline, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 5 more
- Conditions
- Binge Eating Disorder
- Interventions
- dasotraline 4mg, dasotraline 6mg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 44 more
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- dasotraline 4mg, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 2 more
- Conditions
- Depressive Disorder, Major
- Interventions
- SEP-225289, Venlafaxine, placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • Arcadia, California • Beverly Hills, California + 43 more
- Conditions
- Pediatric Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more